Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | Learnings of COVID-19 on transplant and cellular therapies

Katie Maurer • 5 Feb 2021
TCT 2021
General

Katie Maurer, MD, PhD, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, outlines learnings from the ongoing COVID-19 pandemic in the management of patients undergoing transplant and treatment with cellular therapies. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Katie Maurer

0:49
Advances in GvHD and maintenance following transplant
Katie Maurer • 5 Feb 2021
4:33
Impact of COVID-19 on HSCT and cellular therapies in the US
Katie Maurer • 2 Feb 2021

Related Videos

3:11
Exercise as an underutilized tool in cancer care
Rebecca Robinson • 23 Apr 2024
2:30
The impact of conflict on access to cancer therapies
Richard Sullivan • 29 Apr 2024
2:15
Cardiac biomarkers for immune checkpoint inhibitor-related myocarditis in cancer patients
Arjun Ghosh • 25 Apr 2024
1:09
Rethinking healthcare to improve affordability, sustainability, and patient outcomes
Richard Sullivan • 29 Apr 2024
The content of VJHemOnc is intended for healthcare professionals